BostonGene and Exigent Genomic INsight Study

Study Purpose

The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients. Using the BostonGene Tumor Portrait test, the study aims to identify actionable findings, assess feasibility, and determine patient enrollment in clinical trials. Four cohorts of 100 patients each will be studied over two years, focusing on treatment decisions and patient outcomes. This study seeks to demonstrate the clinical utility of genomic testing in guiding therapy for advanced cancer patients in community settings.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational [Patient Registry]
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Patients must have a confirmed malignancy of: Locally recurrent, unresectable, or metastatic breast cancer or; Unresectable stage III or metastatic non-small cell lung cancer or; Unresectable or metastatic melanoma or; Locally advanced or metastatic l sarcoma.
  • - Life expectancy > 3 months as per the treating physician.
  • - Willingness to provide informed consent.
  • - Living in the United States at time of enrollment.
  • - Agree to participate in genomic and molecular profiling.

Exclusion Criteria:

- not meeting the inclusion criteria

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT06272864
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

BostonGene
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry, Other
Overall Status Recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma
Additional Details

The BEGIN Study, conducted by BostonGene and Exigent, is a prospective investigation aimed at evaluating the efficacy and feasibility of comprehensive molecular testing in advanced cancer patients within the community setting. Recent advancements in cancer treatment have led to the integration of targeted and immune-based therapies into standard practice. Recognizing the significance of genomic and molecular alterations in patient therapy selection, BostonGene has developed a high-throughput sequencing platform, the BostonGene Tumor Portrait test, which provides a comprehensive overview of tumors and their microenvironment. The primary objectives of the study include determining the frequency of actionable findings identified by the BostonGene Tumor Portrait test, assessing the feasibility and turnaround time of comprehensive sequencing analysis, and evaluating the frequency of patient enrollment in clinical trials based on test results. Secondary objectives involve determining the frequency of patients receiving molecularly matched therapy, evaluating concordance between DNA and RNA targets, and assessing the impact of test findings on treatment decisions. The study will involve four cohorts of patients with breast cancer, non-small cell lung cancer, melanoma, and sarcoma, each comprising 100 participants. Subjects will be identified through designated pilot sites. The study duration will be up to two years, with data collection including baseline demographics, medical history, treatment decisions, and patient outcomes. Overall, the study aims to elucidate the clinical utility of the BostonGene Tumor Portrait test in guiding treatment decisions for advanced cancer patients in real-world community settings, with a focus on actionable findings, treatment efficacy, and patient outcomes.

Arms & Interventions

Arms

: Breast cancer

Patients with locally recurrent, unresectable or metastatic breast cancer

: NSCLC

Patients with unresectable stage III or metastatic non-small cell lung cancer

: Melanoma

Patients with unresectable or metastatic melanoma

: Sarcoma

Patients with locally advanced or metastatic sarcoma

Interventions

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Highlands Oncology Group, Rogers 4128894, Arkansas 4099753

Status

Recruiting

Address

Highlands Oncology Group

Rogers 4128894, Arkansas 4099753, 72758

Site Contact

Adam Torres

[email protected]

650-773-0771

Stockton 5399020, California 5332921

Status

Recruiting

Address

Stockton Hematology Oncology Medical Group

Stockton 5399020, California 5332921, 95204

Site Contact

Lizbeth Ortiz

[email protected]

650-773-0771

Fort Wayne 4920423, Indiana 4921868

Status

Recruiting

Address

Fort Wayne Medical Oncology and Hematology

Fort Wayne 4920423, Indiana 4921868, 46804

Site Contact

Phil Huston

[email protected]

650-773-0771

New Mexico Cancer Center, Albuquerque 5454711, New Mexico 5481136

Status

Recruiting

Address

New Mexico Cancer Center

Albuquerque 5454711, New Mexico 5481136, 87109

Site Contact

Valerie Tucker

[email protected]

650-773-0771

Tulsa 4553433, Oklahoma 4544379

Status

Recruiting

Address

Oklahoma Cancer Specialists and Research Institute

Tulsa 4553433, Oklahoma 4544379, 74146

Site Contact

Ruth Dunn

[email protected]

650-773-0771

Oncology Consultants, Houston 4699066, Texas 4736286

Status

Recruiting

Address

Oncology Consultants

Houston 4699066, Texas 4736286, 77030

Site Contact

Laura Guerra

[email protected]

650-773-0771

Northwest Medical Specialities, Puyallup 5807575, Washington 5815135

Status

Recruiting

Address

Northwest Medical Specialities

Puyallup 5807575, Washington 5815135, 98373

Site Contact

Malee Chhan

[email protected]

650-773-0771

Stay Informed & Connected